oral tirzepatide studies TrimRX Oral Tirzepatide Pill: FDA-Approved Options

GLP-1 directly activates appetite-control pathways in the brain and slows stomach emptying, triggering significant hunger reduction and sustained weight loss

R.et al (2019)

Washout approach (more common): Administer final Wegovy dose Wait 7 to 10 days (approximately 1.5 half-lives) Start Zepbound 2.5 mg Rationale: minimizes overlapping GLP-1 receptor activation, reduces nausea risk Overlap approach (less common, used when continuous appetite suppression is critical): Administer final Wegovy dose Start Zepbound 2.5 mg 3 to 4 days later Rationale: prevents gap in therapeutic effect during washout Risk: higher nausea and GI side effect burden during overlap window Most providers use washout

29,30 Its also been shown to neutralize free radicals 31,32 and reduce inflammation